- finviz | 2021年07月07日 22:50Lifshitz Law Firm, P.C. Announces Investigation of ADXS, CORE, FFWM and RAAC
- finviz | 2021年07月07日 21:30INVESTIGATION ALERT: Halper Sadeh LLP Investigates USCR, QTS, MCF, ADXS; Shareholders are Encouraged to Contact the Firm
- finviz | 2021年07月07日 17:44Biohaven Leaps After Posting $93M Sales for Migraine Drug
- finviz | 2021年07月07日 02:44SHAREHOLDER ALERT: WeissLaw LLP Investigates Advaxis, Inc.
- finviz | 2021年07月06日 22:48Advaxis Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Merger of Advaxis, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm ADXS
- finviz | 2021年07月06日 20:09Advaxis Stock Shoots Higher On Reverse Merger Agreement With Biosight
- finviz | 2021年07月06日 18:00Advaxis and Biosight Announce Entry into Definitive Merger Agreement
- finviz | 2021年07月06日 17:12Advaxis Jumps on Deal to Be Bought by Biosight
- finviz | 2021年06月15日 04:05Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update
- finviz | 2021年05月20日 05:01Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
- finviz | 2021年04月29日 04:30Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
- finviz | 2021年04月26日 23:07UPDATE - Advaxis Announces Achievement of Second Milestone Under ADXS-HER2 Licensing Agreement with OS Therapies
- finviz | 2021年04月26日 20:00Advaxis Announces Receipt of Second Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies
- finviz | 2021年04月21日 01:06ADVAXIS MAKING BOLD STEPS IN NEW CANCER STUDIES AND AGREEMENT WITH COLUMBIA UNIVERSITY
- finviz | 2021年04月12日 20:30Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- finviz | 2021年04月10日 20:31Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting